Logo Image
Feature|Videos|August 14, 2026

The Road Ahead: Advice for Pharma's Next Board Meeting

Key Takeaways

  • Learn why pharma leaders should build evidence and value demonstration earlier in the drug development lifecycle.
  • Discover why cross-functional collaboration across regulatory, legal, and communications teams is essential to managing risk in a volatile environment.
SHOW MORE

Kirsten Axelsen, Maggie Farley, Rachel Turow, and Julie Tierney close out this Peer Exchange with the one piece of advice each would give a pharma CEO walking into their next board meeting.

Episodes in this series

This closing segment of "Fault Lines: Business, Reputation, and the Politics Reshaping Pharma" brings together health economist Kirsten Axelsen, Maggie Farley of RC Resolve, Rachel Turow of Skadden, and Julie Tierney of Leavitt Partners to synthesize the Peer Exchange's key themes into actionable guidance for pharma leadership.

Each panelist offers one piece of advice for a pharma CEO walking into their next board meeting: Axelsen emphasizes building evidence and value demonstration earlier in the drug development lifecycle; Farley stresses individualized scenario planning paired with the confidence to speak up when a plan is tested; Turow calls for cross-functional collaboration among trusted advisors so no issue is viewed in a vacuum; and Tierney urges companies not to wait for certainty before acting on emerging policy opportunities.

Pharma executives and board members will come away with a concise, practical summary of how to lead through sustained regulatory and policy disruption — grounded in the evidence, scenario planning, collaboration, and decisiveness the panel identifies as most essential.